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Background: In 2000, American Samoa had 16.5% prevalence of lymphatic filariasis (LF) antigenemia. Annual mass
drug administration (MDA) was conducted using single-dose albendazole plus diethylcarbamazine from 2000 to
2006. This study presents the results of a 2007 population-based PacELF C-survey in all ages and compares the
adult filarial antigenemia results of this survey to those of a subsequent 2010 survey in adults with the aim of
improving understanding of LF transmission after MDA.
Results: The 2007 C-survey used simple random sampling of households from a geolocated list. In 2007, the
overall LF antigen prevalence by immunochromatographic card test (ICT) for all ages was 2.29% (95% CI 1.66–3.
07). Microfilaremia prevalence was 0.27% (95% CI 0.09–0.62). Increasing age (OR 1.04 per year, 95% CI 1.02–1.05)
was significantly associated with ICT positivity on multivariate analysis, while having ever taking MDA was protective
(OR 0.39, 95% CI 0.16–0.96). The 2010 survey used a similar spatial sampling design.
The overall adult filarial antigenemia prevalence remained relatively stable between the surveys at 3.32%
(95% CI 2.44–4.51) by ICT in 2007 and 3.23 (95% CI 2.21–4.69) by Og4C3 antigen in 2010. However, there were
changes in village-level prevalence. Eight village/village groupings had antigen-positive individuals identified in
2007 but not in 2010, while three villages/village groupings that had no antigen-positive individuals identified
in 2007 had positive individuals identified in 2010.
Conclusions: After 7 years of MDA, with four rounds achieving effective coverage, a representative household
survey in 2007 showed a decline in prevalence from 16.5 to 2.3% in all ages. However, lack of further decline in
adult prevalence by 2010 and fluctuation at the village level showed that overall antigenemia prevalence at a
broader scale may not provide an accurate reflection of ongoing transmission at the village level.
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Lymphatic filariasis (LF) is a neglected mosquito-borne
parasitic disease caused by three species of filarial parasi-
tes—Wuchereria bancrofti, Brugia malayi and Brugia
timori [1]. In May 1997, the World Health Assembly
passed a resolution calling for the global elimination of
LF as a public health problem by the year 2020. The World
Health Organisation (WHO) subsequently launched the* Correspondence: shaun.coutts@my.jcu.edu.au
1College of Public Health, Medical and Veterinary Sciences, James Cook
University, Cairns, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeGlobal Programme to Eliminate Lymphatic Filariasis
(GPELF) in 2000 to facilitate this aim [2]. In 1999, the
Pacific Programme for the Elimination of Lymphatic
Filariasis (PacELF) was formed to coordinate regional
efforts toward elimination in the 22 Pacific Island
countries and territories (PICTs) by 2020, utilising a
strategy of annual mass drug administration (MDA) of
a single dose of diethylcarbamazine (DEC) plus alben-
dazole for the entire at-risk population [3].
The WHO criteria for ceasing MDA after a minimum
of five effective annual rounds (coverage exceeding 65%
of the total population) in areas where Aedes mosquitosle is distributed under the terms of the Creative Commons Attribution 4.0
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assessment survey (TAS) of 6- to 7-year-old children. Crit-
ical cut-off values are calculated based on sample sizes de-
signed so that a TAS evaluation unit (EU) has at least a 75%
chance of passing if antigenemia is 0.5% and no more than
5% chance of passing if antigenemia is ≥1% [4]. Prior to the
development of the TAS, PacELF had established separate
criteria for ceasing MDA if <1% filarial antigenemia (<2%
upper 95% CI) across all age groups, based on the results of
a population-based cluster survey (C-survey).
American Samoa is an unincorporated territory of the
USA. The population of 54,454 (in 2015) inhabits the
islands of Tutuila, Aunu’u, Ofu-Olosega and Ta’u. The
capital, Pago Pago, is located on Tutuila, the largest is-
land, where >95% of the population reside. The territory
was partitioned from neighbouring Samoa in 1899: how-
ever, the two communities continue to share strong family,
cultural, linguistic and economic bonds. LF in American
Samoa is caused by the diurnally sub-periodic Wuchereria
bancrofti, transmitted predominantly by the day-biting
mosquito Aedes polynesiensis, with the night-biting Aedes
samoanus as a secondary vector [5–7].
LF prevalence surveys have been conducted in Ameri-
can Samoa since 1923, with microfilaremia (Mf) preva-
lence in pre-PacELF surveys as high as 21% in 1962
(n = 1000). MDA with DEC (6 mg/kg monthly for a total
of 72 mg/kg over a year) was undertaken in 1963 and
1965. A follow-up survey in 1968 found Mf prevalence
had decreased to 0.3% (n = 1053 across 13 villages) [3].
No further MDA interventions were recorded until the
commencement of PacELF and the national elimination
programme in 1999, when a nationwide convenience
survey of 18 villages established a baseline prevalence of
16.5% (n = 3018) filarial antigenemia by immunochro-
matographic card test (ICT) [3]. Seven rounds of annual
MDA followed during 2000–2006, targeting the whole
population except pregnant women, children less than
2 years old and the severely ill [8].
MDA coverage in American Samoa was initially poor,
ranging from 19% in 2000 to 49% in 2002. From 2002 to
2005, the national programme was independently evalu-
ated using a variety of formative research methods in-
cluding focus groups with drug distributors (programme
directors, nurses, health assistants and volunteers); a
multi-stage household cluster survey of community
knowledge, attitudes and practices; and key informant
interviews with church leaders. The programme evalu-
ation resulted in significant changes to community mo-
bilisation, behaviour change communication and drug
delivery strategies. Notably, the evaluation identified the
involvement of churches as a key driver of improved
programme coverage, with over half of the population
receiving treatment in conjunction with church attend-
ance [9]. Coverage increased to 71% in 2003 and wassustained at a relatively high level in 2004 (65%), 2005
(67%) and 2006 (70%) [9].
A significant decrease in LF antigen prevalence was
observed in sentinel villages between 2001 and 2006, co-
inciding with the improvements in MDA participation
and coverage [10]. Two spot check village surveys in
2006 (a total of four villages) found higher prevalence
outside of sentinel villages [8, 10, 11].
This paper reports on the results of a 2007
population-based PacELF C-survey and compares the
proportion of antigen-positive adults in 2007 with those
found in a 2010 study for corresponding villages. We
aimed to identify potential risk factors for infection in
2007 and examine small-scale changes in antigenemia
over time by comparing village-level adult seropreva-
lence between the 2007 and 2010 surveys. Furthermore,
we aimed to reflect on how these small-scale variations
in disease transmission may affect post-MDA surveillance
practices and strategies.
Methods
Data sources
The 2007 C-survey data were collected by American
Samoa Department of Health (AS DOH) staff with the
support of staff from the US Centers for Disease Control
and Prevention (US CDC). The survey team used geo-
graphic information systems (GIS) data from the American
Samoa Department of Commerce to identify buildings in
villages on the populated islands of Tutuila, Aunu’u,
Ofu-Olosega and Tau. Under the assumption of an
average household size of five individuals, a simple ran-
dom sample of 540 buildings was taken (500 in Tutuila
and Aunu’u, 20 in Ofu-Olosega, 20 in Tau), with a target
sample size of 2700 individuals. GIS software (ArcGIS, En-
vironmental Systems Research Institute, Redlands, CA)
was used to identify and highlight selected buildings and
generate printed maps for use by survey teams to identify
these households on-ground. All individuals 2 years of age
and older residing in selected households were invited to
participate and tested for filarial antigenemia using ICT
(BinaxNOW Filariasis ICT Alere, Scarborough, USA).
ICT-positive individuals were tested for Mf by micro-
scopic examination of thick blood smears (20 μL of blood,
Giemsa-stained) and treated with DEC and albendazole
[12]. Where possible, those who were absent at the time of
visit were tracked down and tested according to the same
procedure. A standard questionnaire was administered at
the time of testing to collect data on demographics and
MDA compliance history. All individuals involved in the
survey provided verbal consent prior to participation.
The 2010 survey data were collected as part of a lepto-
spirosis seroprevalence study, using a spatially representa-
tive household sampling design similar to the C-survey.
The study was designed to include a representative sample
Table 1 Characteristics of the eligible sampled and missed
population in the 2007 lymphatic filariasis C-survey in American
Samoa
Eligible (%) Sampled (%) Missed (%)
Total 2216 1881 335
Gender
Female 1150 (51.9) 1000 (53.2) 150 (48.8)
Male 1066 (48.1) 881 (46.8) 185 (52.2)
Age group (years)
2–9 293 (13.2) 269 (14.3) 24 (7.2)
10–19 601 (27.1) 512 (27.2) 89 (26.6)
20–29 325 (14.7) 266 (14.1) 59 (17.6)
30–39 330 (14.9) 273 (14.5) 57 (17.0)
40–49 296 (13.4) 235 (12.5) 61 (18.2)
50–59 186 (8.4) 169 (9.0) 17 (5.1)
60 + 185 (8.3) 157 (8.3) 28 (8.4)
Island of residence
Tutuila/Aunu’u 2094 (94.5) 1773 (94.3) 321 (95.8)
Ofu-Olosega 57 (2.6) 53 (2.8) 4 (1.2)
Ta’u 65 (2.9) 55 (2.9) 10 (3.0)
Table 2 W. bancrofti antigenemia prevalence by island group in
the 2007 lymphatic filariasis C-survey in American Samoa
Island No. of participants No. of ICT positive Prevalence (%)
Tutuila/Aunu’u 1773 40 2.26
Ofu-Olosega 53 2 3.77
Ta’u 55 1 1.82
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sampling designs have been previously described [13, 14].
The serum bank was subsequently used for a study of the
seroprevalence and spatial epidemiology of LF in Ameri-
can Samoa after MDA, which identified possible residual
foci of antigen-positive adults [15]. Filarial antigenemia in
stored venous serum samples was measured through the
detection of circulating filarial antigen (CFA) using the
Og4C3 antigen ELISA test (cut-off value of >32 units was
considered seropositive).
Data analysis
The 2007 survey data were entered into Microsoft Excel
before being exported into STATA 13.1 (College Station,
TX), which was used for subsequent analyses. Descrip-
tive statistics were derived from the data to examine the
characteristics of the sample. Univariate logistic regres-
sion analysis was performed on independent variables
(sex, age, years lived in American Samoa, having ever
taken MDA, number of years having taken MDA, island
of residence) to assess association with the dependent
variable (ICT positivity). Years lived in American Samoa
was categorised into <7 and ≥7 years in order to assess
possible differences in risk between individuals who
had lived in American Samoa prior to MDA and those
who had lived in American Samoa only during MDA
(<7 years). All independent variables with a P value of
<0.25 on univariate analysis were considered for inclusion
in a full multivariate logistic regression model. Starting
with all potentially significant independent variables from
the univariate analysis, a backward stepwise regression
procedure (P ≤ 0.05) was performed to refine and select
the final set of variables for inclusion in the multivariate
model.
For comparison of village-level adult filarial antigenemia
prevalence between the 2007 and 2010 surveys, villages in
which five or more individuals were sampled in each
survey were included for analysis. Some small adjacent
villages that did not meet this cut-off were combined
into village groupings for this analysis if the groupings
were considered to be ecologically and geographically
appropriate. Villages which could not be grouped and
did not meet the cut-off were excluded from the compari-
son. As the 2010 survey only sampled adults, individuals
under 18 years of age were excluded from the 2007 data
for the purposes of the comparison.
Results
2007 survey
From a total of 540 buildings selected, 2216 individuals
from 394 buildings were identified as being eligible for
inclusion in the survey. Of these individuals, 1881 were
available for testing and enrolled in the survey. The most
common reasons for an individual being missed by thesurvey (n = 335) were not being home at the time
(59.9%), followed by being at work (22.3%), being off-
island (13.3%) and refusing to participate (4.6%). The
sample population is described in Table 1.
The overall LF antigenemia prevalence for all ages by
ICT was 2.29% (43/1881, 95% CI 1.66–3.07). Table 2
summarises LF antigenemia prevalence by island group.
Variations in village-level LF antigenemia prevalence are
described in Figs. 1 and 2. Four ICT-positive children
aged <10 years were identified, all residents on the island
of Tutuila. Age-specific LF antigenemia prevalence is
shown in Fig. 3.
Microfilaremia prevalence was 0.27% (5/1881, 95% CI
0.09–0.62). Of the five microfilaremic individuals identified,
all resided in different villages on the island of Tutuila.
Three were aged 30–39 and two were aged ≥60 years.
A number of independent variables were significantly
associated with being ICT positive (P < 0.25) on univariate
logistic regression analysis and included in the full multi-
variate model. Table 3 provides a summary of associations
between independent variables and ICT positivity on
univariate logistic regression analysis.
Fig. 1 Village-level filarial antigenemia prevalence in the 2007 lymphatic filariasis C-survey in American Samoa—Tutuila and Aunu’u
Fig. 2 2007 village-level filarial antigenemia prevalence in the 2007 lymphatic filariasis C-survey in American Samoa—Ofu-Olosega and Tau
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Fig. 3 Age-specific prevalence for W. bancrofti antigenemia in the 2007 lymphatic filariasis C-survey in American Samoa. Bars indicate 95%
confidence intervals
Table 3 Association between variables and immunochromatographic card test (ICT) positivity on univariate logistic regression
analysis for the 2007 lymphatic filariasis C-survey in American Samoa
No. of participants ICT positive Prevalence (%) Univariate OR (95% CI) P value
Gender
Female 1000 18 1.80 Reference
Male 881 25 2.84 1.59 (0.86–2.94) 0.14
Age
1-year increments 1881 43 2.29 1.04 (1.02–1.05) <0.001
Years lived in AS
<7 years 303 9 2.97 1.39 (0.66–2.92) 0.39
≥7 years 1575 34 2.16 Reference
Ever taken MDA
No 109 6 5.50 Reference
Yes 1763 37 2.10 0.37 (0.15–0.89) 0.03
Years taken MDA
0 115 6 5.22 Reference
1 134 6 4.48 0.85 (0.27–2.72) 0.79
2 183 3 1.64 0.3 (0.07–1.24) 0.10
3 218 2 0.92 0.17 (0.03–0.85) 0.03
4 256 7 2.73 0.51 (0.17–1.55) 0.24
5 647 13 2.01 0.37 (0.14–1.00) 0.05
6 299 6 2.01 0.37 (0.12–1.18) 0.09
7 9 0 0.00 – –
Island of residence
Tutuila 1773 40 2.26 Reference
Ofu-Olosega 53 2 3.77 1.7 (0.4–7.22) 0.47
Ta’u 55 1 1.82 0.8 (0.11–5.94) 0.83
Italicized type indicates significance for inclusion in the full multivariate model
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Table 4 Variables significantly associated with
immunochromatographic card test (ICT) positivity on multivariate
logistic regression analysis in the 2007 lymphatic filariasis C-survey
in American Samoa
Variable Adjusted odds
ratio
95% confidence
interval
P
value
Age (1-year
increments)
1.04 1.02–1.05 <0.001
Ever taken MDA 0.39 0.16–0.96 0.04
Table 5 Village-level adult filarial antigenemia prevalence in the 200
Village/village grouping 2007
Tested
2007
ICT positive
2007
% positive
Aasu Fou/Aoloau Fou 22 1 4.55
Afao/Amaluia/Asili 7 0 0
Agugulu/Nua/Seetaga 29 0 0
Alao 13 0 0
Alega/Amaua/Auto/Avaio 21 0 0
Amouli 17 1 5.88
Aoa 7 0 0
Aua 39 3 7.69
Auasi/Utumea East 12 0 0
Aumi/Laulii 22 1 4.55
Aunuu 10 0 0
Fagaalu 22 3 13.64
Fagaitua/Pagai 13 1 7.69
Fagali’i 8 0 0
Fagasa 10 0 0
Fagatogo 27 0 0
Faleasao/Fitiuta/Tau 31 1 3.23
Faleniu 22 2 9.09
Ili’ili 39 1 2.56
Leone 89 1 1.12
Malaeimi 39 2 5.13
Malaeloa 17 1 5.88
Mesepa 16 0 0
Ofu 19 2 10.53
Olosega 10 0 0
Pago Pago 88 2 2.27
Pavaiai 70 2 2.86
Tafuna 135 3 2.22
Taputimu 10 0 0
Tula 7 0 0
Vaitogi 30 2 6.67
Italicized type indicates statistical significance at the .05 level
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remained significantly associated with ICT positivity in
the final multivariate logistic regression model, while
having ever taken part in an MDA round was protective
(OR 0.39, 95% CI 0.16–0.96). Table 4 provides a summary
of the final multivariate logistic regression model.
Adult filarial antigenemia—comparison between the 2007
and 2010 surveys
The adult filarial antigenemia was 3.32% (95% CI 2.44–
4.51) by ICT in 2007 and 3.23% (95% CI 2.21–4.69) by
Og4C3 in 2010. The overall adult filarial antigenemia
prevalence remained relatively stable between the surveys.7 and 2010 lymphatic filariasis surveys in American Samoa
95% CI 2010
Tested
Og4C3
Positive
2010
% positive
95% CI
0.12–22.84 35 1 2.86 0.07–4.92
0–40.96 50 2 4.00 0.49–13.71
0–11.94 28 0 0 0–12.34
0–24.71 19 0 0 0–17.65
0–16.11 23 2 8.70 1.07–28.04
0.15–28.69 18 1 5.56 0.14–27.29
0–40.96 15 0 0 0–21.80
1.62–20.87 22 1 4.55 0.12–22.84
0–26.46 13 0 0 0–24.71
0.12–22.84 23 0 0 0–14.82
0–30.85 16 0 0 0–20.59
2.91–34.91 17 0 0 0–19.51
0.19–36.03 19 0 0 0–17.65
0–36.94 13 4 30.77 9.09–61.43
0–30.85 17 0 0 0–19.51
0–12.77 21 0 0 0–16.11
0.08–16.70 43 0 0 0–8.22
1.12–29.16 18 0 0 0–18.53
0.06–13.48 23 4 17.39 4.95–38.78
0.03–6.10 20 0 0 0–16.84
0.77–20.81 28 1 3.57 0.09–18.35
0.15–28.69 30 3 10.00 2.11–26.53
0–20.59 7 0 0 0–40.96
1.30–33.14 11 0 0 0–28.49
0–30.85 14 0 0 0–23.16
0.28–7.97 73 2 2.74 0.33–9.55
0.35–9.94 16 1 6.25 0.16–30.23
0.46–6.36 21 0 0 0–16.11
0–30.85 14 0 0 0–23.16
0–40.96 26 0 0 0–13.23
0.82–22.07 7 1 14.29 0.36–57.87
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comparison, consisting of 23 individual villages and eight
village groupings (of between two to four villages).
Antigen-positive individuals were identified in both the
2007 and 2010 surveys in nine (29.0%) of the 31 vil-
lages/village groupings. Eight (25.8%) village/village
groupings had antigen-positive individuals identified in
2007 but not in 2010, while three (9.6%) villages/village
groupings that had no antigen-positive individuals
identified in 2007 had positive individuals identified in
2010. Table 5 describes village-level filarial antigenemia
in the 2007 and 2010 surveys.
The largest discrepancies in proportions of antigen-
positive adults between 2007 and 2010 were in the vil-
lages of Fagali’i (0 to 33.77%, P = 0.08), Ili’ili (2.56 to
17.39%, P = 0.04), Faga’alu (13.64 to 0%, P = 0.11) and
Ofu (10.53 to 0%, P = 0.27). Figure 4 illustrates the
changes in filarial antigenemia prevalence in villages/
village groupings between 2007 and 2010.
Discussion
Since the commencement of PacELF in 1999, when a
nationwide mapping survey established a baseline preva-
lence of 16.5% antigenemia, American Samoa has made
significant progress toward the elimination of LF. A
timeline of LF programme activities in American Samoa
is presented in Table 6. Antigenemia declined to 2.29%Fig. 4 Comparison of overall and village-level adult filarial antigenemia
prevalence between the 2007 and 2010 lymphatic filariasis surveys in
American Samoain all ages by 2007 after four effective rounds of annual
MDA; however, overall antigen prevalence in adults
stayed relatively constant over the subsequent 3 years
(3.32% in 2007 (ICT) and 3.23% in 2010 (Og4C3 anti-
gen)). Despite remaining at an overall low level, village-
based data from the two independent surveys suggest
fluctuation in antigen prevalence among adults in some
villages.
Both the 2007 and 2010 studies showed a broad distri-
bution of a few infected individuals with some clustering
within villages, demonstrating that significant geographic
heterogeneity can exist even in such a small island set-
ting. This widespread, low-level distribution has also
been demonstrated in a 2011 molecular xenomonitoring
study [16]. A subsequent study that compared results of
the 2010 human seroprevalence study and the 2011 en-
tomology study provided evidence for good concordance
between results from serology and molecular xenomoni-
toring during post-MDA surveillance in American
Samoa [17].
The 2007 survey results did not meet the PacELF criter-
ion of filarial antigenemia <1% (upper CI <2%) for ceasing
MDA. The PacELF technical working group recom-
mended that American Samoa undertake an additional
round of MDA in 2008; however, this was not accom-
plished because of limited resources. Even in the absence
of additional MDA, American Samoa conducted and
passed a TAS in 2011, with a school-based survey of 1st
and 2nd graders on Tutuila (n = 949, approximating to
the 6- to 7-year-old age group) identifying two ICT-
positive individuals (0.21%), below the critical cut-off value
of six individuals. The two ICT-positive individuals
attended the same school on Tutuila, but lived in different
villages [18]. A subsequent 2010 seroepidemiological study
of adults (using samples originally collected for a lepto-
spirosis study) found evidence of spatial clustering of
antigen-positive individuals in two villages on Tutuila
(Fagali’i and Ili’ili), suggesting possible residual foci of
transmission post-MDA. One of the villages included the
school where the two antigen-positive children were iden-
tified in the 2011 TAS. Analysis of the demographic data
indicated that adult males and recent migrants were at
higher risk of LF antigenemia and demonstrated antibody
positivity. This association suggests adults may serve as
the primary reservoirs for continued transmission, despite
low prevalence in younger age groups [15].
TAS and the PacELF C-survey are not designed to
provide village-level prevalence estimates, but rather es-
timates of mean prevalence across an evaluation unit of
one or more districts, which was a territory-wide estimate
in this island setting. The comparisons between surveys
confirm that these cross-sectional survey methods may
not always provide an accurate reflection of antigenemia
at the smaller-scale village level as expected, given the
Table 6 Timeline of lymphatic filariasis programme activities in American Samoa, 1999–2011
Year Activity Survey population
size
Age
group
Prevalence
(% antigenemia, ICT)
MDA coverage (% total
population treated)
1999 Nationwide mapping (convenience survey) [3] 3018 (18 villages) All 16.5
2000 MDA [9] 19
2001 MDA [9] 51
2001 Sentinel survey [10] 1024 (4 villages) All 11.52
2002 MDA [9] 49
2003 Drug distributor evaluation
Community KAP survey
Programme modifications [9]
2003 MDA [9] 71
2003 Drug distributor evaluation
Church leader survey Programme modifications [9]
2003 Sentinel survey [10] 917 (4 villages) All 13.74
2004 MDA [9] 65
2004 Drug coverage survey [9] 86
2005 MDA [9] 67
2006 MDA [9] 70
2006 Sentinel survey [10] 1371 (4 villages) All 0.95
2006 Purposeful survey [11] 569 (3 villages) >5 years 4.22
2007 Random household C-survey (spatial sampling
design)
1881 (national) All 2.29
2010 Random household survey (spatial sampling design) [15] 807 (national) ≥18 years 3.2 (Og4C3 antigen
ELISA)
2011 TAS [18] 949 6–7 years 0.21
ELISA enzyme-linked immunosorbent assay, ICT immunochromatographic card test, KAP knowledge, attitudes, practices, MDA mass drug administration,
TAS transmission assessment survey
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sidual transmission may not be identified which could
then serve as areas of potential resurgence. Discrepancies
in filarial antigenemia prevalence within some villages be-
tween 2007 and 2010 may suggest that foci of local trans-
mission have developed in some villages and declined in
others over a relatively short time period. However, these
discrepancies could also be explained by limitations in the
sampling method, sample sizes and tests used for the
comparison.
The findings should be considered in light of the
study’s limitations. Although both surveys utilised a
similar random spatial sampling method, the 2007 study
included multiple adults from the majority of house-
holds, while the 2010 study only included one person
from the majority of households. No adjustment for
clustering within households (which would have widened
the confidence intervals around the prevalence estimate)
was made for the 2007 dataset, although at the observed
level of prevalence it would be expected to have had negli-
gible effect. A further limitation is that the 2007 survey
used ICT, while in 2010, stored serum samples collected for
a different survey were tested for Og4C3 antigen [15]. Both
tests measure circulating filarial antigen, but comparison ishampered by lack of a true gold standard. A multi-country
comparison of ICT and Og4C3 antigen in multiple field
laboratories concluded that although positive concord-
ance was unexpectedly low at individual level, there
was no difference in the prevalence estimates given by
the two tests at a population level [19]. More recent
studies have shown that concordance between the two
tests is much greater when using serum/plasma (as
done in this study) rather than dried blood spots for
Og4C3 antigen testing [20].
Conclusions
The variability in village-level antigenemia within the
2007 and 2010 surveys suggests that there remains a
significant gap in knowledge regarding LF transmission
dynamics at small spatial scales. Further research and a
greater understanding of these transmission dynamics,
their impact on LF elimination efforts and how to accur-
ately assess significant residual infection may become in-
creasingly important as more countries move into the
post-MDA phase and continue to work toward elimin-
ation. This research should include further longitudinal
studies in villages or areas in which increases or a lack of
decline in prevalence has been observed.
Coutts et al. Tropical Medicine and Health  (2017) 45:22 Page 9 of 10In American Samoa specifically, programmatic priorities
to support the elimination of LF should include ongoing
investigation and surveillance of hotspots identified during
surveys, targeted testing and treatment of known high-risk
groups and the comparison of TAS results in children
against prevalence in older age groups.
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